Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
about
Treatment of diffuse large B cell lymphomaNF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma.Transcriptional and apoptotic responses of THP-1 cells to challenge with toxigenic, and non-toxigenic Bacillus anthracis.Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinomaA phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancerBortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Inhibiting NF-κB activation by small molecules as a therapeutic strategy.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsA phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancerEarly tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.ΔNp63 versatilely regulates a Broad NF-κB gene program and promotes squamous epithelial proliferation, migration, and inflammationTargeting NF-κB in mouse models of lung adenocarcinoma.Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.Current and potential inflammation targeted therapies in head and neck cancer.Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients.Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.Inhibition of protein degradation induces apoptosis through a microtubule-associated protein 1 light chain 3-mediated activation of caspase-8 at intracellular membranes.Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions.PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHNFunctional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding.Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus.Analysis of NF-κB Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome—A Children's Oncology Group Study
P2860
Q27006062-2DFD8364-0AF2-4CBD-AF7A-FE6C538A6933Q30300214-FF0F4E72-BBA7-4A5D-BF1A-DFCA13DB86E3Q30440528-C0C145FB-0438-4FBA-B603-E39D4C88874CQ30489022-057D3AC9-3DDC-4BEC-BD43-474DF88CA617Q33388541-F3005B4E-E691-4136-BBA0-DC67A04B2A7FQ33751186-9F880BD0-0B71-45BC-9820-450FD8FD13DDQ33946183-319F7C06-048C-49E7-A383-8F89DE7BD49FQ33989444-8AF7F47F-CCBA-4968-86E8-A93831CC9D3BQ34163076-32A979C8-2D84-4607-8CB3-B30E3DFE4F8CQ34205025-EBA0C2B4-CFB3-4FFC-A40B-588223710262Q34218976-2F410220-0571-480F-90FD-EAEEF4972A3FQ34615116-DE736B6F-4286-4C2F-A399-4B73F23FEF2AQ35154029-B8395BFA-BE07-4A34-8E1E-66BD604F6093Q35501271-C7335BAD-1B60-4D31-A083-2A98830C98DFQ36012652-0D273653-226B-482F-BF7C-4C9C864F62A5Q36192439-72AA6DC8-3255-47FE-997D-9684B5C24750Q36238438-335C19B7-A08F-45BD-81B4-44CD0A98C8B7Q36478306-5A810535-933C-4ED3-9644-A4EFD125C652Q36776444-F2973682-8C5F-4DCE-9281-B786102B4BF1Q37060950-AE0F3A94-92D3-49EF-AE7A-4899C92251A6Q37189951-42260189-67D8-46F7-AA00-EAE4D0173A56Q37316179-298A21B5-DAC1-477B-A303-3AB61B0F8C9CQ37414399-FA9E7204-BC8F-4DA9-A872-0341EDE5B749Q37589257-D64D26D5-858D-4246-BEA8-0BD35ED67849Q37706051-E2D6C902-EE14-411A-B96E-9FC6068B3FA2Q38837839-DC165410-B779-4882-9013-AC06280EAD72Q38986185-BB00A222-EA2D-4BB2-B375-E28A36F229D0Q39155870-01962203-7A08-4AC2-A8CD-5C9080C07A62Q39289240-2619A01E-88C2-4102-84D9-51BFAB51BE84Q39532979-3B5D1FB8-72FE-4527-ACA8-4C3CB603EC86Q39623358-98B4B00F-42AD-486A-92B0-A8178FBA342EQ39689340-DD54CC8D-6955-4A87-A2A8-121EFFF7F943Q39819746-02983ED9-9977-4A39-9876-8E1C73F64254Q42355050-7062D65C-662C-4028-98C0-668DF08E75CEQ47582263-D5E28CD8-C11F-45A9-85CA-D3553A7DD117Q55084684-A9BF9F46-A9DB-42B2-B686-80A223412A54Q58698930-DE0BD631-E948-4503-B34F-4B3641BE128E
P2860
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@en
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@nl
type
label
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@en
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@nl
prefLabel
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@en
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@nl
P2093
P1476
Bortezomib-induced apoptosis w ...... units in head and neck cancer.
@en
P2093
Carter Van Waes
Clint Allen
Kunal Saigal
Liesl Nottingham
Pattatheyil Arun
Zhong Chen
P304
P356
10.1158/1078-0432.CCR-07-4470
P407
P577
2008-07-01T00:00:00Z